Clinical Trials Logo

Alzheimer Disease, Early Onset clinical trials

View clinical trials related to Alzheimer Disease, Early Onset.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05754021 Active, not recruiting - Alzheimer Disease Clinical Trials

A Practical Platform for In-Home Remote Monitoring of Cognitive Frailty

Start date: February 1, 2022
Phase:
Study type: Observational

Cognitive frailty, characterized by the coexistence of physical frailty and cognitive impairment, is a robust indicator of cognitive decline. Recognizing its significance, the International Association of Gerontology and Geriatrics and the International Academy on Nutrition and Aging have advocated for the use of cognitive frailty assessment as a means of monitoring the progression of mild cognitive impairment towards debilitating conditions like dementia, Alzheimer's disease, and loss of independence. Despite the clear need, a practical and remotely accessible tool for measuring cognitive frailty is currently lacking, especially within the context of telehealth visits. With telehealth video-conferencing becoming increasingly popular, accepted by healthcare payers, and preferred by older adults who may face difficulties traveling to a clinic, there is a pressing need for a software-based solution for remote cognitive frailty assessment that can be easily integrated into existing telehealth systems. This study proposes designing and validating a video-based solution to remotely monitor cognitive-frailty in older adults.

NCT ID: NCT04552795 Active, not recruiting - Clinical trials for Alzheimer Disease, Early Onset

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

ART-AD
Start date: February 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and tolerability in patients with early stage Alzheimer's disease. This study will provide the initial data on target engagement and Alzheimer's disease-relevant outcomes for future trials.

NCT ID: NCT03661034 Active, not recruiting - Alzheimer Disease Clinical Trials

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

Start date: May 31, 2018
Phase: N/A
Study type: Interventional

The Etude Study is a multi-center, four-arm prospective dose-adjusting study designed to assess the tolerability, safety and efficacy of non-invasive sensory stimulation for patients with cognitive impairment.

NCT ID: NCT03625401 Active, not recruiting - Clinical trials for Alzheimer Disease, Early Onset

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

ROAD
Start date: October 4, 2018
Phase: Phase 2
Study type: Interventional

multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.

NCT ID: NCT03069391 Active, not recruiting - Aging Clinical Trials

The Interactive Physical and Cognitive Exercise System

iPACES™
Start date: March 4, 2017
Phase: N/A
Study type: Interventional

This study is intended to clarify the benefits to brain health and thinking processes that result from different forms of exercise. In particular, this study will investigate the possible benefits of physical exercise (such as pedaling an under-table stationary elliptical) or mental exercise (such as playing a videogame on a portable tablet), or combining these activities together (as in the iPACES™ exergame).